BioSpace News Archive

Beyond Air, Inc. and, through its affiliate Beyond Cancer announced that the Company is scheduled to participate in a fireside chat at the LifeSci Partners HealthTech Symposium being held virtually September 20-21, 2022.

Annexon, Inc. announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the closing of its previously announced underwritten public offering of 13,900,000 shares of Common Stock at a public offering price of $9.00 per share.

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved the fixed-dose combination of Opdualag (nivolumab and relatlimab) for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumor cell PD-L1 expression < 1%.

DermTech, Inc. announced the grant to 30 new employees of restricted stock units representing the contingent right to receive up to an aggregate of 459,896 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan.

Predictive Oncology announced that J. Melville Engle will retire as Chief Executive Officer and as Chairman and a member of the company’s Board of Directors.

Ocugen, Inc. announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 148,800 shares of its common stock and restricted stock units covering an aggregate of 40,092 shares of common stock to five newly hired team members.

bluebird bio, Inc. announced the U.S. Food and Drug Administration has granted Accelerated Approval of SKYSONA®, also known as eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for Beyfortus® for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants during their first RSV season.

DNA Script, a world leader in Enzymatic DNA Synthesis for DNA on demand, won the Grand Prize Trophy at the 2022 Future Unicorns Awards, whose ceremony took place on September 15, 2022, at the Bourrienne Hotel.